Behandlingen af BRAF-muteret metastatisk melanom med BRAF/MEK-inhibitorer bedrer prognosen

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Behandlingen af BRAF-muteret metastatisk melanom med BRAF/MEK-inhibitorer bedrer prognosen. / Boyles, Tessa Bystrup; Svane, Inge Marie; Bastholt, Lars; Schmidt, Henrik.

In: Ugeskrift for Laeger, Vol. 178, V02160126, 2016.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Boyles, TB, Svane, IM, Bastholt, L & Schmidt, H 2016, 'Behandlingen af BRAF-muteret metastatisk melanom med BRAF/MEK-inhibitorer bedrer prognosen', Ugeskrift for Laeger, vol. 178, V02160126. <http://ugeskriftet.dk/videnskab/behandlingen-af-braf-muteret-metastatisk-mela-nom-med-braf-mek-haemmere-bedrer-prognosen>

APA

Boyles, T. B., Svane, I. M., Bastholt, L., & Schmidt, H. (2016). Behandlingen af BRAF-muteret metastatisk melanom med BRAF/MEK-inhibitorer bedrer prognosen. Ugeskrift for Laeger, 178, [V02160126]. http://ugeskriftet.dk/videnskab/behandlingen-af-braf-muteret-metastatisk-mela-nom-med-braf-mek-haemmere-bedrer-prognosen

Vancouver

Boyles TB, Svane IM, Bastholt L, Schmidt H. Behandlingen af BRAF-muteret metastatisk melanom med BRAF/MEK-inhibitorer bedrer prognosen. Ugeskrift for Laeger. 2016;178. V02160126.

Author

Boyles, Tessa Bystrup ; Svane, Inge Marie ; Bastholt, Lars ; Schmidt, Henrik. / Behandlingen af BRAF-muteret metastatisk melanom med BRAF/MEK-inhibitorer bedrer prognosen. In: Ugeskrift for Laeger. 2016 ; Vol. 178.

Bibtex

@article{61c461c3f221445bacd617a70a9b6b7e,
title = "Behandlingen af BRAF-muteret metastatisk melanom med BRAF/MEK-inhibitorer bedrer prognosen",
abstract = "Melanoma is an aggressive form of skin cancer which is the cause of a great number of skin cancer-related deaths worldwide and about 300 deaths in Denmark. After several years of failure of treatment of metastatic melanoma, the development of BRAF- and later MEK inhibitors was considered revolutionary. Treatment with BRAF inhibitors alone and especially in combination with a MEK inhibitor improves outcome for patients with BRAF V600-mutated metastatic melanoma. However, even when treated with the combination of the inhibitors, many patients develop acquired resistance within a year.",
keywords = "English Abstract, Journal Article",
author = "Boyles, {Tessa Bystrup} and Svane, {Inge Marie} and Lars Bastholt and Henrik Schmidt",
year = "2016",
language = "Dansk",
volume = "178",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",

}

RIS

TY - JOUR

T1 - Behandlingen af BRAF-muteret metastatisk melanom med BRAF/MEK-inhibitorer bedrer prognosen

AU - Boyles, Tessa Bystrup

AU - Svane, Inge Marie

AU - Bastholt, Lars

AU - Schmidt, Henrik

PY - 2016

Y1 - 2016

N2 - Melanoma is an aggressive form of skin cancer which is the cause of a great number of skin cancer-related deaths worldwide and about 300 deaths in Denmark. After several years of failure of treatment of metastatic melanoma, the development of BRAF- and later MEK inhibitors was considered revolutionary. Treatment with BRAF inhibitors alone and especially in combination with a MEK inhibitor improves outcome for patients with BRAF V600-mutated metastatic melanoma. However, even when treated with the combination of the inhibitors, many patients develop acquired resistance within a year.

AB - Melanoma is an aggressive form of skin cancer which is the cause of a great number of skin cancer-related deaths worldwide and about 300 deaths in Denmark. After several years of failure of treatment of metastatic melanoma, the development of BRAF- and later MEK inhibitors was considered revolutionary. Treatment with BRAF inhibitors alone and especially in combination with a MEK inhibitor improves outcome for patients with BRAF V600-mutated metastatic melanoma. However, even when treated with the combination of the inhibitors, many patients develop acquired resistance within a year.

KW - English Abstract

KW - Journal Article

M3 - Tidsskriftartikel

C2 - 27592869

VL - 178

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

M1 - V02160126

ER -

ID: 181025806